A research published in JAMA Network Open emphasizes the discrepancy amongst what it prices to create copyright as well as retail costs individuals confront. Regardless of the very low manufacturing expenses, Novo Nordisk has not publicly disclosed unique figures for copyright or its other item, Wegovy.In October 2024, Novo Nordisk printed a study